{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:43:39Z","timestamp":1740120219034,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11307-022-01733-1","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T15:37:19Z","timestamp":1651160239000},"page":"830-841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["[18F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton\u2019s Tyrosine Kinase"],"prefix":"10.1007","volume":"24","author":[{"given":"Marc B.","family":"Skaddan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin W.","family":"Wooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle C.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Voorbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaozhong J.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly D.","family":"Foster-Duke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Hickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srirajan","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee D.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann E.","family":"Tovcimak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Comley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd J.","family":"Finnema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9476-8170","authenticated-orcid":false,"given":"Sarah R.","family":"Mudd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"1733_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A (2018) Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18:148\u2013167","journal-title":"Nat Rev Cancer"},{"key":"1733_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17:57","journal-title":"Mol Cancer"},{"key":"1733_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-019-00635-7","volume":"14","author":"F Lucas","year":"2019","unstructured":"Lucas F, Woyach JA (2019) Inhibiting Bruton\u2019s Tyrosine Kinase in CLL and Other B-Cell Malignancies. Target Oncol 14:125\u2013138","journal-title":"Target Oncol"},{"key":"1733_CR4","doi-asserted-by":"publisher","first-page":"78917","DOI":"10.18632\/oncotarget.20551","volume":"8","author":"L Jacobs","year":"2017","unstructured":"Jacobs L, Habringer S, Slawska J et al (2017) Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma. Oncotarget 8:78917\u201378929","journal-title":"Oncotarget"},{"key":"1733_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/jlcr.3872","volume":"63","author":"K Dahl","year":"2020","unstructured":"Dahl K, Turner T, Vasdev N (2020) Radiosynthesis of a Bruton\u2019s tyrosine kinase inhibitor, [(11) C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation. J Label Compd Radiopharm 63:482\u2013487","journal-title":"J Label Compd Radiopharm"},{"key":"1733_CR6","doi-asserted-by":"crossref","unstructured":"Lindberg A, Boyle AJ, Tong J et al (2021) Radiosynthesis of [11C]Ibrutinib via Pd-Mediated [11C]CO Carbonylation: Preliminary PET Imaging in Experimental Autoimmune Encephalomyelitis Mice. Front Nucl Med","DOI":"10.3389\/fnume.2021.772289"},{"key":"1733_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682","journal-title":"Nat Methods"},{"key":"1733_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2967\/jnumed.109.068858","volume":"51","author":"JA Disselhorst","year":"2010","unstructured":"Disselhorst JA, Brom M, Laverman P et al (2010) Image-quality assessment for several positron emitters using the NEMA NU 4\u20132008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med 51:610\u2013617","journal-title":"J Nucl Med"},{"key":"1733_CR9","first-page":"455","volume":"46","author":"YC Tai","year":"2005","unstructured":"Tai YC, Ruangma A, Rowland D et al (2005) Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46:455\u2013463","journal-title":"J Nucl Med"},{"key":"1733_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11307-016-0992-3","volume":"19","author":"X Zhou","year":"2017","unstructured":"Zhou X, Elsinga PH, Khanapur S, Dierckx RA, de Vries EF, de Jong JR (2017) Radiation Dosimetry of a Novel Adenosine A2A Receptor Radioligand [(11)C]Preladenant Based on PET\/CT Imaging and Ex Vivo Biodistribution in Rats. Mol Imaging Biol 19:289\u2013297","journal-title":"Mol Imaging Biol"},{"key":"1733_CR11","doi-asserted-by":"publisher","unstructured":"DepMap Broad (2022)\u00a0DepMap 22Q1 Public. figshare. Dataset.\u00a0https:\/\/doi.org\/10.6084\/m9.figshare.19139906.v1","DOI":"10.6084\/m9.figshare.19139906.v1"},{"key":"1733_CR12","doi-asserted-by":"publisher","first-page":"e64795","DOI":"10.1371\/journal.pone.0064795","volume":"8","author":"HH Cheng","year":"2013","unstructured":"Cheng HH, Yi HS, Kim Y et al (2013) Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One 8:e64795","journal-title":"PLoS One"},{"key":"1733_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","volume":"14","author":"DA Bond","year":"2019","unstructured":"Bond DA, Woyach JA (2019) Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep 14:197\u2013205","journal-title":"Curr Hematol Malig Rep"},{"key":"1733_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.drudis.2016.09.020","volume":"22","author":"SR Mudd","year":"2017","unstructured":"Mudd SR, Comley RA, Bergstrom M et al (2017) Molecular imaging in oncology drug development. Drug Discov Today 22:140\u2013147","journal-title":"Drug Discov Today"},{"key":"1733_CR15","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075\u201313080","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1733_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","volume":"10","author":"J Rip","year":"2019","unstructured":"Rip J, de Bruijn MJW, Appelman MK, Pal Singh S, Hendriks RW, Corneth OBJ (2019) Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease. Front Immunol 10:95","journal-title":"Front Immunol"},{"key":"1733_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban X, Arnold DL, Weber MS et al (2019) Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. N Engl J Med 380:2406\u20132417","journal-title":"N Engl J Med"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/cpt.1056","volume":"103","author":"AE Herman","year":"2018","unstructured":"Herman AE, Chinn LW, Kotwal SG et al (2018) Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton\u2019s Tyrosine Kinase Inhibitor. Clin Pharmacol Ther 103:1020\u20131028","journal-title":"Clin Pharmacol Ther"},{"key":"1733_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S et al (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374:323\u2013332","journal-title":"N Engl J Med"},{"key":"1733_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31:88\u201394","journal-title":"J Clin Oncol"},{"key":"1733_CR21","first-page":"511","volume":"23","author":"MR Francesco","year":"2017","unstructured":"Francesco MR, Wong M, LaStant J et al (2017) PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibits efficacy in central nervous system immunity. Mult Scler J 23:511\u2013511","journal-title":"Mult Scler J"},{"key":"1733_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","volume":"81","author":"L Goldwirt","year":"2018","unstructured":"Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S (2018) Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol 81:783\u2013789","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01733-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T07:19:29Z","timestamp":1666163969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01733-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01733-1","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"type":"print","value":"1536-1632"},{"type":"electronic","value":"1860-2002"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}